News

The study will start in the second quarter of this year at Memorial Sloan Kettering Cancer Center in New York. Clinical costs will be shared by the companies.

The orphan drug status to the drug, Epidiolex, entitles GW Pharmaceuticals to a seven-year exclusive market period. TSC is the third orphan indication that the company is targeting

AbbVie and CytomX will jointly develop and commercialize probody drug conjugates directed against CD71, which is highly expressed several solid and hematologic cancers. Under the deal, CytomX will

The new Center, located on the SBP campus in La Jolla, will bring together experts from SBP and GSK to investigate factors that influence brain function and potentially

Under the terms of the agreement, Yabao will exclusively own rights to commercialize certain Salus Pharma-developed products outside the U.S. and to manufacture for worldwide markets, while Salus

The round was co-led by Pfizer Venture Investments and Roche Venture Fund, and brings the combined total investment in the company to $59 million. The round also included

The agency placed the hold last month after elevated serum sodium levels were found in four patients who received the highest dose of 5 ug/kg. Cara Therapeutics’ analysis

TSC is a rare genetic disorder affecting about one million people globally, and Afinitor is the only approved non-surgical option indicated to treat non-cancerous brain and kidney tumours

Under the terms of the agreement, Evotec will manage Pierre Fabre’s compound collection (individual compounds and collection plates) out of its state-of-the-art compound management facility in Toulouse, France.